MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Avanos Medical Net Debt 2011-2026 | AVNS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Avanos Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.7 M | 28.5 M | 84.5 M | 111 M | 26.2 M | 84 M | 120 M | -137 M | 361 M | 465 M | 449 M | 487 M | -32.2 M | 28 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 487 M | -137 M | 149 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Electromed
ELMD
|
-10.5 M | $ 25.3 | 0.8 % | $ 214 M |  USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.0 | 0.76 % | $ 1.22 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.04 | 0.72 % | $ 17.6 M | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 12.96 | -0.84 % | $ 1.75 B | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 14.75 | 0.75 % | $ 346 M | USA |
 |
LivaNova PLC
LIVN
|
-282 M | $ 58.86 | -0.1 % | $ 3.21 B |  Britain |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.35 | 1.06 % | $ 125 M |  France |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
PAVmed
PAVM
|
710 K | $ 8.54 | -4.32 % | $ 5.73 M | USA |
 |
Insulet Corporation
PODD
|
468 M | $ 167.15 | 4.46 % | $ 11.8 B | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
3.85 M | $ 10.44 | 0.97 % | $ 296 M | USA |
 |
Sintx Technologies
SINT
|
-898 K | $ 2.07 | 4.02 % | $ 5.74 M | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
11 M | $ 0.63 | -1.29 % | $ 39.2 M | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Stryker Corporation
SYK
|
11 B | $ 316.51 | 0.49 % | $ 121 B | USA |
 |
Tactile Systems Technology
TCMD
|
-75.4 M | $ 22.36 | -0.62 % | $ 511 M | USA |
 |
TELA Bio
TELA
|
5.33 M | $ 0.94 | 9.29 % | $ 44.1 M | USA |
 |
Tandem Diabetes Care
TNDM
|
239 M | $ 18.53 | 2.04 % | $ 1.26 B | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | USA |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
Varex Imaging Corporation
VREX
|
225 M | $ 11.38 | 3.13 % | $ 471 M | USA |
 |
Vivos Therapeutics
VVOS
|
-888 K | $ 0.83 | 6.36 % | $ 8.53 M | USA |
 |
Butterfly Network
BFLY
|
-65.9 M | $ 4.55 | -7.52 % | $ 963 M | USA |
 |
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
-511 M | $ 88.88 | 1.24 % | $ 12 B | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 10.28 | 0.69 % | $ 368 M | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 37.15 | 3.31 % | $ 1.15 B | USA |
 |
Inspire Medical Systems
INSP
|
-433 M | $ 53.58 | 0.32 % | $ 1.57 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.18 B | $ 85.0 | 1.59 % | $ 2.95 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 81.56 | 0.43 % | $ 47.7 B | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |